With over 27 years of biopharmaceutical industry experience, WuXi Biologics’ Executive Vice President and Chief Technology Officer, Dr. Sherry Gu has established extensive expertise in cell line, upstream and downstream development and portfolio management while in her various roles at WuXi Biologics and in her well-established career in the biopharmaceutical industry. Dr Sherry Gu joined WuXi Biologics in 2017 and built a strong CMC team in the U.S. & EU. She was instrumental in establishing WuXi Biologics’ global footprint and business growth by leveraging the company’s strong technical capabilities, robust global capacity, and service flexibility. Dr. Sherry Gu received her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and worked for 2 years at Bristol Myers Squibb and 18 years at Eli Lilly and Company. During her time at Lilly, she made significant technical contributions including establishing the mammalian cell culture platform, which enabled multiple Lilly bioproduct approvals, including Dulaglutide, Ixekizummab, and upcoming Galcanezumab. She also had several significant leadership roles, including Director of Cell Line & Upstream Development, Director of Downstream Development, Program Team Leader, and AutoImmune Portfolio Leader, which helped her gain a deep understanding of drug development throughout the product lifecycle.